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introduction: Primary prevention measures are needed to lower the incidence of sudden cardiac death (SCD) in the general population. Aspirin 
(ASA) and Vitamin E (VitE) both have potential antiarrhythmic properties and have been studied in primary prevention of cardiovascular disease 
(CVD). Results have been conflicting for CVD mortality, and the impact of these interventions on SCD has not been well studied.
methods:  We performed a fixed effect meta-analysis examining the relationship of randomized treatment with ASA (Physicians’ Health Study I and 
Women’s Health Study) and VitE (Physicians’ Health Study II and Women’s Health Study) with SCD in three primary prevention randomized trials 
comprising a total 76,588 subjects. Similar methods to confirm SCD, defined as death within one hour of the onset of symptoms, were utilized.
results: There were 91 and 127 SCD cases confirmed during the ASA and VitE trials respectively. In both the individual and combined analyses 
(Table), ASA and VitE were not significantly associated with SCD. In the combined analysis, ASA and VitE were associated with non-significant 22% 
and 8% reductions in SCD risk, respectively.
conclusion: Randomized treatment with ASA and VitE did not significantly lower SCD risk in these primary prevention populations. Although this 
meta-analysis represents the largest to date, the rarity of SCD in these healthy populations limits our ability to exclude moderate reductions in SCD 
risk conferred by these agents.
Table 
Study Subjects (N) SCD (N) HR 95% CI Combined
ASA Physicians’ Health Study I 22,071 45 0.80 0.45-1.44
0.78 [0.52-1.18]
Women’s Health Study 39,876 46 0.77 0.43-1.37
VitE Physicians’ Health Study II 14,641 81 0.99 0.64-1.54
0.92 [0.66-1.27]
Women’s Health Study 39,876 46 0.84 0.47-1.50
